We believe omadacycline will be used in the emergency room, hospital, and community settings. We have designed omadacycline to provide significant advantages over existing antibiotics, including activity against resistant bacteria, broad spectrum of coverage, intravenous, or IV, and oral formulations with once-daily dosing, and a favorable safety and tolerability profile. We believe that it will become the primary antibiotic choice of physicians for use as a first-line monotherapy for acute bacterial skin and skin structure infections, or ABSSSI, community-acquired bacterial pneumonia, or CABP, urinary tract infections, or UTI, and other serious community-acquired bacterial infections.
Our second most advanced product candidate, WC 3035, is a novel tetracycline-derived compound designed for use in the treatment of acne and rosacea. WC 3035 has demonstrated favorable anti-inflammatory activity, narrow-spectrum antibacterial activity relative to other tetracycline-derived molecules, oral bioavailability, and favorable pharmacokinetic, or PK, properties which we believe make it particularly well-suited for the treatment of acne and rosacea in the community setting. We have licensed rights to WC 3035 for the treatment of acne and rosacea in the United States to a subsidiary of Actavis (formerly Warner Chilcott), while retaining rights in the rest of the world. Actavis is responsible for the clinical development of WC 3035 for the treatment of acne in the United States, following a successful phase 2 clinical trial; a phase 3 clinical trial is planned for the second half of 2014 of this product candidate for this indication.
In addition to omadacycline and WC 3035, we have advanced a series of product candidates through to proof of concept in animal models. We designed these next generation, tetracycline-derived, new molecular entities using our proprietary drug development platform, and incorporated the recognized immune-modulation, anti-inflammatory, and other properties of the tetracycline class. We believe that, based on our preclinical testing to date, the potential for these small molecule therapies to treat debilitating neurological and inflammatory diseases such as multiple sclerosis, spinal muscular atrophy, rheumatoid arthritis, and inflammatory bowel disease, is promising. In addition, we have an early-stage program focused on the treatment of Clostridium difficile associated diarrhea, as well as a program focused on important animal health diseases.
The Paratek team enjoys a broad range of management experience developed across the biotechnology and pharmaceutical sectors.
|May 01, 2013||Paratek Pharmaceuticals Announces Expanded FDA Grant of Qualified Infectious Disease Product (QIDP) Designation for Its Lead Product Candidate, Omadacycline|
|Jan 03, 2013||Paratek Pharmaceuticals Announces FDA Grant of Qualified Infectious Disease Product (QIDP) Designation for its Lead Product Candidate, Omadacycline|
|Sep 28, 2012||Paratek Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering|
|May 22, 2012||Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors|
|Mar 28, 2012||Paratek Wins Agreement with FDA on Special Protocol Assessment (SPA) for Phase3 Study in Community-Acquired Bacterial Pneumonia|
|Sep 10, 2010||Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy|
To contact Paratek investor relations, please email us at email@example.com.
Poster Presented at 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 9-12, 2012
Posters Presented at 22nd European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), March 30-April 3, 2011
Antimicrobial Activity of PTK 0796 (Omadacycline) and Comparator Agents Against Contemporary Pathogens Commonly Associated with Community-Acquired Respiratory Tract Infections Collected During 2011 from the European Union
Poster Presented at 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17-20, 2011
Posters Presented at 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) / 27th International Congress of Chemotheraphy (ICC), May 7-10, 2011
In a phase 2 complicated skin and soft tissue infections trial, outcomes assessed early in the course of therapy were consistent with outcomes 10-17 days after completing therapy with either omadacycline (OMC; PTK796) or linezolid, Poster P1528
Posters Presented at 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 12-15, 2010
Poster Presented at Annual European League Against Rheumatism (EULAR) Congress, June 10-13, 2009
Posters Presented at 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 25-28, 2008
Poster Presented at 15th International Inflammation Research Association Conference, September 21-24, 2008
Poster Presented at 60th Annual Meeting of the American Academy of Neurology, April 12-19, 2008
Poster Presented at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 18, 2007
Poster Presented at 107th General Meeting of the American Society for Microbiology (ASM), May 22, 2007
Posters Presented at 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 30, 2006
Posters Presented at 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 15, 2003
Paratek Pharmaceuticals, Inc.
75 Kneeland Street
We are looking for highly motivated, bright, and committed individuals to join our team. If you would like to be considered for positions at Paratek, please submit your resume by email to: firstname.lastname@example.org.
Paratek Pharmaceuticals, Inc. is an Equal Opportunity Employer.
Via MBTA: Take Red Line to South Station. Go left onto Atlantic Avenue. Go right onto Kneeland Street. Enter 75 Kneeland Street; take the elevator to the 6th floor. We are through the door on the left.
From Mass Turnpike East: Follow turnpike East to exit 24a/SouthStation, and go left onto Kneeland Street off the exit ramp. Enter 75 Kneeland Street and take the elevator to the 6th floor. We are through the door on the left. (Parking instructions are given below.)
From 93 North: Take exit 20, follow signs for South Station. Make a left at the fourth stop light onto Kneeland Street. Enter 75 Kneeland Street; take the elevator to the 6th floor. We are through the door on the left. (Parking instructions are given below.)
From 93 South: Take exit 23/Purchase Street, as you come out of the tunnel follow roadway as it winds through construction and becomes Purchase St. Continue through financial district on Purchase street across Congress, Summer and Lincoln Streets. Continue along Purchase Street as you approach Chinatown the road becomes Surface Artery, continue until the light at Kneeland Street and make a left onto Kneeland. Enter 75 Kneeland Street; take the elevator to the 6th floor. We are through the door on the left. (Parking instructions are given below.)
Parking (on Tyler): From Kneeland Street, go to Tyler Street. Make a right and park on the left at the open-air parking lot.
Parking (at New England Medical Center): Continue on Kneeland to Washington Street. Make a left and follow signs for Parking.